Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol vs Remimazolam for Neurophysiological Monitoring in Spine Surgery
NCT04968054Completed
- Sponsor
- Gangnam Severance Hospital
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of remimazolam in ossification of the posterior longitudinal ligament (OPLL) and cervical spondylotic myelopathy (CSM), sponsored by Gangnam Severance Hospital. Primary endpoint: Latency of Somatosensory Evoked Potentials. Started Jul 2021; status: completed.
02
Drugs
remimazolam
03
Conditions
ossification of the posterior longitudinal ligament (OPLL)cervical spondylotic myelopathy (CSM)
Beyond the preview
Go deeper on NCT04968054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968054.